Statistics for Larimar Therapeutics, (id:6724 LRMR)

Valuation metrics

Market cap

391.13M

Enterprise value

189.60M

Trailing P/E (ttm)

-7.35

Forward P/E

-3.98

PEG ratio

-3.98

Price/Sales (ttm)

Price/Book (mrq)

1.97

Enterprise Value/Revenue

Enterprise Value/EBITDA

-2.58

Overview

Shares outstanding

63.81M

Float

31.93M

Shares short

2.72M

% Held by insiders

0.01%

% Held by institutions

1.07%

Average volume (10 days)

747.34K

Average volume (90 days)

Price summary

52-Week low

3.19

52-Week high

13.68

52-Week change

42.70%

Beta

0.71

50-Day moving average

7.29

200-Day moving average

8.13

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

May 29th, 2020

Ex-dividend date

Last split factor

2:1

Last split date

May 29th, 2020

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

0.00%

Operational effectiveness

Return on assets

-28.55%

Return on equity

-44.50%

Income statement

Revenue (ttm)

0.00

Revenue per share (ttm)

0.00

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-73,437,000.00

Net income to common (ttm)

-64,773,000.00

Diluted EPS (ttm)

-1.15

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

203.71M

Total cash per share (mrq)

3.19

Total debt (mrq)

5.36M

Total Debt/Equity (mrq)

2.70

Current ratio (mrq)

1.31K%

Book value per share (mrq)

3.11

Cash flow

Cash flow statement

-58,288,000.00

Levered free cash flow (LFCF)

-35,223,376.00